Home » Stocks » KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. (KALV)

Stock Price: $15.31 USD 0.07 (0.46%)
Updated Oct 26, 2020 2:47 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 274.17M
Revenue (ttm) 9.32M
Net Income (ttm) -32.59M
Shares Out 17.91M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $15.31
Previous Close $15.24
Change ($) 0.07
Change (%) 0.46%
Day's Open 15.01
Day's Range 14.88 - 15.39
Day's Volume 11,771
52-Week Range 5.61 - 19.41

More Stats

Market Cap 274.17M
Enterprise Value 210.84M
Earnings Date (est) Dec 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 17.91M
Float 11.76M
EPS (basic) -1.83
EPS (diluted) -1.83
FCF / Share -2.09
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 247,888
Short Ratio 5.38
Short % of Float 2.11%
Beta 2.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 29.41
PB Ratio 3.70
Revenue 9.32M
Operating Income -45.41M
Net Income -32.59M
Free Cash Flow -37.27M
Net Cash 63.32M
Net Cash / Share 3.54
Gross Margin -295.08%
Operating Margin -487.21%
Profit Margin -349.70%
FCF Margin -399.88%
ROA -27.86%
ROE -36.97%
ROIC -45.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$28.14*
(83.80% upside)
Low
21.0
Current: $15.31
High
33.0
Target: 28.14
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year202020192018201720162015201420132012
Revenue12.6916.138.391.502.13-0.030.421.54
Revenue Growth-21.31%92.13%458.11%-29.49%---93.01%-73.02%-
Gross Profit12.6916.138.391.502.13-0.030.421.54
Operating Income-40.53-29.82-18.71-22.34-15.18-9.89-11.68-5.22-1.83
Net Income-29.12-20.82-15.81-18.60-11.44-7.23-13.36-5.68-2.05
Shares Outstanding17.7515.0810.324.650.590.260.040.030.03
Earnings Per Share-1.64-1.38-1.53-4.47-26.17-34.94-305.33-187.88-71.96
Operating Cash Flow-44.82-36.3710.56-23.72-13.16-6.37-11.25-4.86-1.84
Capital Expenditures-0.22-1.08-1.43-0.07-0.01-0.13-0.16-0.02-0.09
Free Cash Flow-45.04-37.459.13-23.80-13.17-6.49-11.41-4.88-1.93
Cash & Equivalents67.7110151.0630.9521.76-3.959.83-
Total Debt1.06-0.28---6.573.06-
Net Cash / Debt66.6610150.7830.9521.76--2.626.77-
Assets92.5311861.3934.3524.75-6.6410.11-
Liabilities8.7821.3934.143.0261.86-11.274.26-
Book Value83.7596.7427.2531.33-37.11--44.18-33.71-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name KalVista Pharmaceuticals, Inc.
Country United States
Employees 56
CEO T. Andrew Crockett

Stock Information

Ticker Symbol KALV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KALV

Description

KalVista Pharmaceuticals, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.